Who agrees to Antibody treatment for high-risk Covid-19 patients?

Many are saying that who agrees to Antibody treatment for high-risk covid-19 patients. However, if a patient needs an urgent boost, this process can be handy, says WHO.

Antibody treatment approved by WHO
Antibody treatment approved by WHO

WHO on Antibody treatment:

The World Health Organisation (WHO) Antibody treatment for high-risk Covid-19 patients. Regeneron for Covid-19, but only in cases with special health profiles.

High-risk COVID-19 patients:

Persons with non-severe Covid-19 who are although at high risk of hospitalisation can take the antibody combo, as should critically ill cases unable to mount a sufficient immune response, according to a WHO finding published in BMJ.

The Regeneron cocktail of synthetic antibodies — casirivimab and imdevimab — deletes the risk of hospitalisation for unvaccinated. Elderly or immunosuppressed patients with Covid three clinical claims that have yet to be peer-reviewed.

“For all other covid-19 patients, any advantages of this antibody therapy are unlikely to be significant,” the WHO concluded.

Biotech Firm:

Created by biotech firm Regeneron and sold by pharmaceutical giant Roche under Ronapreve. US President Donald Trump got this treatment during his battle with coronavirus.

The monoclonal antibodies casirivimab and imdevimab bind to the SARS-CoV-2 spike protein, offsetting the virus’s capacity to infect cells. The WHO “embraces the room of another therapeutic to the world’s stockpile against COVID-19”, but showed concern about the result of high prices on health inequality.

Given the immense cost and low availability of the key therapy, [global health agency] UNITAID is consulting with Roche Pharmaceutical … for more economical prices and equitable sharing across all regions, especially in low- and middle-income nations.

WHO is also in talks with the company to donate and distribute the drug through UNICEF.”

The UN health officials also called on other companies to submit “bio-similar” versions of the drug for permission. In July, Japan became the leading country to fully approve Regeneron’s antibody therapy for light to moderate Covid-19. The antibody combination is use in different countries and regions, including the European Union, US, India, Switzerland and Canada.

Prince Abdullah Al-Faisal stadium reopen. 

Similar Articles



Please enter your comment!
Please enter your name here



Most Popular